PTH(1-34)治疗术后甲状旁腺功能减退症:2年前瞻性开放标签研究
这项意大利多中心前瞻性开放标签研究纳入42例成人术后甲状旁腺功能减退症患者,给予每日两次皮下注射PTH(1-34) 20 μg治疗24个月。结果显示血清钙从基线至3个月显著升高并维持稳定,钙和维生素D补充需求减少,SF-36全部8个维度评分显著改善。研究表明PTH(1-34)治疗术后甲状旁腺功能减退症有效且安全,可能改善患者躯体和心理健康。
要点
- 每日两次皮下注射PTH(1-34) 20 μg可使术后甲状旁腺功能减退症患者血清钙显著升高并维持稳定。
- 治疗期间钙和维生素D补充需求减少,血清磷逐渐下降,碱性磷酸酶和尿钙排泄逐渐增加。
- SF-36全部8个维度平均评分显著改善(P < 0.001),提示生活质量的躯体和心理健康方面可能获益。
核心结论
- 本研究表明PTH(1-34)治疗成人术后甲状旁腺功能减退症有效且安全。
- PTH(1-34)可能改善患者的躯体和心理健康。
研究设计与样本
- 前瞻性开放标签研究,意大利多中心开展。
- 纳入42例成人术后甲状旁腺功能减退症受试者。
- 干预为每日两次皮下注射PTH(1-34) 20 μg,疗程24个月。
主要发现
- 平均血清钙从基线7.6 ± 0.6 mg/dL升至3个月8.9 ± 1.1 mg/dL(P < 0.001),此后维持稳定至研究结束,同时钙和维生素D补充减少。
- 血清磷从基线4.3 ± 1.1 mg/dL逐渐降至6个月3.9 ± 0.6 mg/dL(P < 0.019),维持稳定至24个月。
- 血清碱性磷酸酶和尿钙排泄从基线至24个月逐渐增加。
- SF-36显示全部8个维度平均评分显著改善(P < 0.001)。
关键数值与推荐
- PTH(1-34)剂量为20 μg,每日两次皮下注射。
- 血清钙主要终点比较:基线7.6 ± 0.6 mg/dL vs 3个月8.9 ± 1.1 mg/dL(P < 0.001)。
- 血清磷比较:基线4.3 ± 1.1 mg/dL vs 6个月3.9 ± 0.6 mg/dL(P < 0.019)。
- SF-36全部8个维度平均评分改善,P < 0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Daily parathyroid hormone (PTH) (1-34) administrations can reduce the required total daily dose of calcium and calcitriol and restore normocalcemia in refractory hypoparathyroidism. However, most PTH(1-34) trials have been conducted on small cohorts including subjects with hypoparathyroidism of various etiologies, and quality of life (QOL) was not investigated. OBJECTIVE: To investigate the effects of 24-month PTH(1-34) treatment in a homogeneous cohort of adult subjects with postoperative hypoparathyroidism and to evaluate QOL changes. DESIGN: Prospective open-label study. SETTING: Italian multicenter study. PARTICIPANTS: 42 subjects. INTERVENTION: Twice-daily PTH(1-34) 20 μg subcutaneous injection. MAIN OUTCOME MEASURES: Calcium and vitamin D supplementation requirements, serum calcium, phosphate, and urinary calcium excretion (3, 6, 12, 18, 24 months). At baseline and at 6 and 24 months, QOL was evaluated by the RAND 36-Item Short Form (SF-36) Health Survey, covering eight domains of physical and mental health. RESULTS: Mean serum calcium concentration significantly increased from baseline to 3 months (7.6 ± 0.6 vs 8.9 ± 1.1 mg/dL, P < 0.001) and remained stable until the end of the study, despite reductions in calcium and vitamin D supplementation. Phosphate levels gradually decreased from baseline to 6 months (4.3 ± 1.1 vs 3.9 ± 0.6 mg/dL, P < 0.019), remaining stable until 24 months. Serum alkaline phosphatase and calcium excretion gradually increased from baseline to 24 months. Data from SF-36 showed a significant improvement in the mean scores of all eight domains (P < 0.001). CONCLUSION: This study demonstrates the efficacy and safety of PTH(1-34) to treat adult patients with postsurgical hypoparathyroidism. PTH(1-34) may improve their mental and physical health.
引用
- Palermo A, Santonati A, Tabacco G, et al. PTH(1-34) for Surgical Hypoparathyroidism: A 2-Year Prospective, Open-Label Investigation of Efficacy and Quality of Life. J Clin Endocrinol Metab. 2018. PMID: 29099939. doi:10.1210/jc.2017-01555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。